For pharmaceutical players, innovations like Pharmaniaga Bhd’s (KL:PHARMA) locally produced recombinant insulin, which received National Pharmaceutical Regulatory Agency (NPRA) approval in November, is set to launch in the first quarter of 2025, which reflects the sector’s evolution towards meeting chronic disease demands.

https://theedgemalaysia.com/node/737010

https://www.thestar.com.my/business/business-news/2024/12/02/trading-ideas-tnb-pharmaniaga-hextar-industries-lbs-sapura-energy-public-bank-kenanga-rhb-padini-takaful-ql-mah-sing-press-metal-aax-velesto